Development of a NIRF Labelled cRGD Peptide with a TCO Tag for Image-Guided Surgery and Postoperative Radiotherapy
 
Our primary objective is the development of the NIRF labelled contrast reagent and TCO tag with optimised affinity and selectivity for neovasculature structures, specifically αvβ3 integrins, associated with carcinomas.

Our secondary objective is to optimise a rapid bio-orthogonal reaction for targeted imaging and radiotherapy. In other words, the tumour-targeting (ZW800-1-cRGD-TCO) construct will be conjugated to a small radiolabelled tetrazine probe.

Overview of all packages...